A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Co

CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia

(2015) Diana Passaro et al.   CANCER CELL

CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance

(2015) Lauren A. Pitt et al.   CANCER CELL

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

(2015) Edward Allan R. Sison et al.   Oncotarget

Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia

(2014) Ashok Srinivasan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

(2014) M. D. Galsky et al.   CLINICAL CANCER RESEARCH

MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism

(2013) Edward Allan R. Sison et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML

(2013) E. A. R. Sison et al.   MOLECULAR CANCER RESEARCH

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

(2011) Steven J. Lemery et al.   BRITISH JOURNAL OF HAEMATOLOGY

Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update

(2011) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving outcomes for high-risk ALL: Translating new discoveries into clinical care

(2011) Stephen P. Hunger et al.   PEDIATRIC BLOOD & CANCER

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

(2010) Simón Méndez-Ferrer et al.   NATURE

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

(2009) John F. DiPersio et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

(2008) S Tavor et al.   LEUKEMIA